Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay

European Journal of Pharmacology

Volumn 660, Issue 1, 2011, Pages 139-147

  Pantel, Jacques ^a   Williams, Savannah Y ^a   Mi, Dehui ^a   Sebag, Julien ^a   Corbin, Jackie D ^a   Weaver, C David ^a   Cone, Roger D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric modulator; cAMP assay; High throughput screen; MC4R; Melanocortin 4 receptor

Indexed keywords

ALPHA INTERMEDIN; CELECOXIB; CYCLIC AMP; DERACOXIB; MELANOCORTIN 4 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; OSTHOLE; PENTOSALEN; PHOSPHODIESTERASE INHIBITOR; PRENYLETIN; ROFECOXIB; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; BIOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; CYCLIC AMP; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUMINESCENT MEASUREMENTS; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PSORALENS; RECEPTOR, MELANOCORTIN, TYPE 4; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TIME FACTORS;

EID: 79955936241     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.031     Document Type: Article

References (47)

1. Ariga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M.P., Jin, S.L., Conti, M., 2004. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173, 7531-7538. (Pubitemid 39628194)
2. Baillie, G.S., 2009. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J. 276, 1790-1799.
3. Blount, M.A., Zoraghi, R., Ke, H., Bessay, E.P., Corbin, J.D., Francis, S.H., 2006. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol. Pharmacol. 70, 1822-1831.
4. Burgin, A.B., Magnusson, O.T., Singh, J., Witte, P., Staker, B.L., Bjornsson, J.M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A.S., Stewart, L.J., Gurney, M.E., 2010. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol. 28, 63-70.
5. Calton, M.A., Ersoy, B.A., Zhang, S., Kane, J.P., Malloy, M.J., Pullinger, C.R., Bromberg, Y., Pennacchio, L.A., Dent, R., McPherson, R., Ahituv, N., Vaisse, C., 2009. Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum. Mol. Genet. 18, 1140-1147.
6. Case, J.B., Fick, J.L., Rooney, M.B., 2010. Proximal duodenal perforation in three dogs following deracoxib administration. J. Am. Anim. Hosp. Assoc. 46, 255-258.
7. Chen, J., Chiou, W.F., Chen, C.C., Chen, C.F., 2000. Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro. J. Urol. 163, 1975-1980. (Pubitemid 30366797)
8. Cherry, J.A., Davis, R.L., 1999. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407, 287-301.
9. Cone, R.D., 2005. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 8, 571-578.
10. Conn, P.J., Christopoulos, A., Lindsley, C.W., 2009. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54.
11. Conti, M., Beavo, J., 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511.
12. DiPilato, L.M., Cheng, X., Zhang, J., 2004. Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc. Natl. Acad. Sci. USA 101, 16513-16518.
13. Farooqi, S., O'Rahilly, S., 2006. Genetics of obesity in humans. Endocr. Rev. 27, 710-718.
14. Govaerts, C., Srinivasan, S., Shapiro, A., Zhang, S., Picard, F., Clement, K., Lubrano-Berthelier, C., Vaisse, C., 2005. Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26, 1909-1919. (Pubitemid 41354549)
15. Greenfield, J.R.,Miller, J.W., Keogh, J.M., Henning, E., Satterwhite, J.H., Cameron, G.S., Astruc, B.,Mayer, J.P., Brage, S., See, T.C., Lomas, D.J., O'Rahilly, S., Farooqi, I.S., 2009. Modulation of blood pressure by centralmelanocortinergic pathways. N. Engl. J. Med. 360, 44-52.
16. Hansen, G., Jin, S., Umetsu, D.T., Conti, M., 2000. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. USA 97, 6751-6756.
17. He, J.Y., Zhang, W., He, L.C., Cao, Y.X., 2007. Imperatorin induces vasodilatation possibly via inhibiting voltage dependent calcium channel and receptor-mediated Ca2+ influx and release. Eur. J. Pharmacol. 573, 170-175.
18. Hinney, A., Bettecken, T., Tarnow, P., Brumm, H., Reichwald, K., Lichtner, P., Scherag, A., Nguyen, T.T., Schlumberger, P., Rief,W., Vollmert, C., Illig, T.,Wichmann, H.E., Schafer, H., Platzer, M., Biebermann, H., Meitinger, T., Hebebrand, J., 2006. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor genemutations in a representative population-based sample and obese adults from Germany. J. Clin. Endocrinol. Metab. 91, 1761-1769.
19. Hruby, V.J., Lu, D., Sharma, S.D., Castrucci, A.L., Kesterson, R.A., Al-Obeidi, F.A., Hadley,M.E., Cone, R.D., 1995. Cyclic lactam α-melanotropin analogues of Ac-Nle4-c[Asp4, D-Phe7, Lys10]α-MSH(4- 10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 38, 3454-3461.
20. Ivey, F.D., Wang, L., Demirbas, D., Allain, C., Hoffman, C.S., 2008. Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases. J. Biomol. Screen. 13, 62-71.
21. Jin, S.L., Richard, F.J., Kuo, W.P., D'Ercole, A.J., Conti, M., 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad. Sci. USA 96, 11998-12003.
22. Kenakin, T., 2007. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28, 407-415.
23. Kuo, P.L., Hsu, Y.L., Chang, C.H., Chang, J.K., 2005. Osthole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells. J. Pharmacol. Exp. Ther. 314, 1290-1299.
24. Liang, H.J., Suk, F.M., Wang, C.K., Hung, L.F., Liu, D.Z., Chen, N.Q., Chen, Y.C., Chang, C.C., Liang, Y.C., 2009. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. Chem. Biol. Interact. 181, 309-315.
25. Luszczki, J.J.,Wojda, E., Andres-Mach,M., Cisowski,W., Glensk,M., Glowniak, K., Czuczwar, S.J., 2009. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res. 85, 293-299.
26. Lynch, M.J., Baillie, G.S., Mohamed, A., Li, X., Maisonneuve, C., Klussmann, E., van Heeke, G., Houslay, M.D., 2005. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 280, 33178-33189.
27. Marnett, L.J., 2009. The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 49, 265-290.
28. May, L.T., Leach, K., Sexton, P.M., Christopoulos, A., 2007. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51.
29. McNulty, J.C., Jackson, P.J., Thompson, D.A., Chai, B., Gantz, I., Barsh, G.S., Dawson, P.E., Millhauser, G.L., 2005. Structures of the agouti signaling protein. J. Mol. Biol. 346, 1059-1070.
30. Menniti, F.S., Faraci, W.S., Schmidt, C.J., 2006. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5, 660-670.
31. Mountjoy, K.G., Mortrud, M.T., Low, M.J., Simerly, R.B., Cone, R.D., 1994. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 8, 1298-1308.
32. Ogawa, H., Sasai, N., Kamisako, T., Baba, K., 2007. Effects of osthol on blood pressure and lipidmetabolisminstroke-prone spontaneously hypertensive rats. J. Ethnopharmacol. 112, 26-31. (Pubitemid 46702410)
33. Peluso,M.R., 2006. Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, andmodulate lipid homeostasis inadipose tissue and liver.Exp.Biol.Med.(Maywood) 231, 1287-1299.
34. Perez-Torres, S., Miro, X., Palacios, J.M., Cortes, R., Puigdomenech, P., Mengod, G., 2000. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]roliprambinding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 20, 349-374.
35. Rich, T.C., Tse, T.E., Rohan, J.G., Schaack, J., Karpen, J.W., 2001. In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors. J. Gen. Physiol. 118, 63-78.
36. Roberts, E.S., Van Lare, K.A., Marable, B.R., Salminen, W.F., 2009. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J. Vet. Pharmacol. Ther. 32, 329-337.
37. Spina, D., 2008. PDE4 inhibitors: current status. Br. J. Pharmacol. 155, 308-315.
38. Srinivasan, S., Lubrano-Berthelier, C., Govaerts, C., Picard, F., Santiago, P., Conklin, B.R., Vaisse, C., 2004. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114, 1158-1164.
39. Stefan, E., Aquin, S., Berger, N., Landry, C.R., Nyfeler, B., Bouvier, M., Michnick, S.W., 2007. Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc. Natl. Acad. Sci. USA 104, 16916-16921.
40. Titus, S., Neumann, S., Zheng, W., Southall, N., Michael, S., Klumpp, C., Yasgar, A., Shinn, P., Thomas, C.J., Inglese, J., Gershengorn, M.C., Austin, C.P., 2008. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J. Biomol. Screen. 13, 120-127.
41. Wikberg, J.E., Mutulis, F., 2008. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov. 7, 307-323.
42. Willoughby, D., Cooper, D.M., 2008. Live-cell imaging of cAMP dynamics. Nat. Methods 5, 29-36.
43. Zhang, J.H., Chung, T.D., Oldenburg, K.R., 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73.
44. Zhang, J., Ma, Y., Taylor, S.S., Tsien, R.Y., 2001. Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc. Natl. Acad. Sci. USA 98, 14997-15002.
45. Zhang, H.T., Huang, Y., Jin, S.L., Frith, S.A., Suvarna, N., Conti, M., O'Donnell, J.M., 2002. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27, 587-595.
46. Zhang, H.T., Huang, Y., Masood, A., Stolinski, L.R., Li, Y., Zhang, L., Dlaboga, D., Jin, S.L., Conti, M., O'Donnell, J.M., 2008. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33, 1611-1623. (Pubitemid 351684706)
47. Zhang, R., Maratos-Flier, E., Flier, J.S., 2009. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150, 3076-3082.